NovoCure Statistics
Total Valuation
NovoCure has a market cap or net worth of $2.06 billion. The enterprise value is $1.83 billion.
Important Dates
The last earnings date was Thursday, April 24, 2025, before market open.
| Earnings Date | Apr 24, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NovoCure has 111.49 million shares outstanding. The number of shares has increased by 1.68% in one year.
| Current Share Class | 111.49M |
| Shares Outstanding | 111.49M |
| Shares Change (YoY) | +1.68% |
| Shares Change (QoQ) | +1.67% |
| Owned by Insiders (%) | 9.64% |
| Owned by Institutions (%) | 81.58% |
| Float | 100.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.23 |
| Forward PS | 3.33 |
| PB Ratio | 5.70 |
| P/TBV Ratio | 5.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.94 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.47, with a Debt / Equity ratio of 1.92.
| Current Ratio | 1.47 |
| Quick Ratio | 1.41 |
| Debt / Equity | 1.92 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.84 |
Financial Efficiency
Return on equity (ROE) is -45.52% and return on invested capital (ROIC) is -10.18%.
| Return on Equity (ROE) | -45.52% |
| Return on Assets (ROA) | -8.64% |
| Return on Invested Capital (ROIC) | -10.18% |
| Return on Capital Employed (ROCE) | -32.42% |
| Revenue Per Employee | $417,817 |
| Profits Per Employee | -$110,340 |
| Employee Count | 1,488 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 3.45 |
Taxes
In the past 12 months, NovoCure has paid $34.37 million in taxes.
| Income Tax | 34.37M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +49.84% in the last 52 weeks. The beta is 0.65, so NovoCure's price volatility has been lower than the market average.
| Beta (5Y) | 0.65 |
| 52-Week Price Change | +49.84% |
| 50-Day Moving Average | 18.85 |
| 200-Day Moving Average | 20.39 |
| Relative Strength Index (RSI) | 55.75 |
| Average Volume (20 Days) | 863,689 |
Short Selling Information
The latest short interest is 5.14 million, so 4.61% of the outstanding shares have been sold short.
| Short Interest | 5.14M |
| Short Previous Month | 5.42M |
| Short % of Shares Out | 4.61% |
| Short % of Float | 5.10% |
| Short Ratio (days to cover) | 7.07 |
Income Statement
In the last 12 months, NovoCure had revenue of $621.71 million and -$164.19 million in losses. Loss per share was -$1.51.
| Revenue | 621.71M |
| Gross Profit | 480.70M |
| Operating Income | -163.88M |
| Pretax Income | -141.13M |
| Net Income | -164.19M |
| EBITDA | -153.51M |
| EBIT | -163.88M |
| Loss Per Share | -$1.51 |
Full Income StatementBalance Sheet
The company has $929.13 million in cash and $696.73 million in debt, giving a net cash position of $232.40 million or $2.08 per share.
| Cash & Cash Equivalents | 929.13M |
| Total Debt | 696.73M |
| Net Cash | 232.40M |
| Net Cash Per Share | $2.08 |
| Equity (Book Value) | 361.96M |
| Book Value Per Share | 3.25 |
| Working Capital | 346.00M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$30.46 million and capital expenditures -$41.68 million, giving a free cash flow of -$72.14 million.
| Operating Cash Flow | -30.46M |
| Capital Expenditures | -41.68M |
| Free Cash Flow | -72.14M |
| FCF Per Share | -$0.65 |
Full Cash Flow StatementMargins
Gross margin is 77.32%, with operating and profit margins of -26.36% and -26.41%.
| Gross Margin | 77.32% |
| Operating Margin | -26.36% |
| Pretax Margin | -20.88% |
| Profit Margin | -26.41% |
| EBITDA Margin | -24.69% |
| EBIT Margin | -26.36% |
| FCF Margin | n/a |
Dividends & Yields
NovoCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.68% |
| Shareholder Yield | n/a |
| Earnings Yield | -7.96% |
| FCF Yield | -3.50% |
Dividend DetailsAnalyst Forecast
The average price target for NovoCure is $32.83, which is 77.56% higher than the current price. The consensus rating is "Buy".
| Price Target | $32.83 |
| Price Target Difference | 77.56% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 20.10% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NovoCure has an Altman Z-Score of 0.52 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.52 |
| Piotroski F-Score | 4 |